Modera Wealth Management LLC Has $262,000 Stock Position in Cencora, Inc. (NYSE:COR)

Modera Wealth Management LLC increased its holdings in Cencora, Inc. (NYSE:COR) by 16.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,167 shares of the company’s stock after acquiring an additional 162 shares during the period. Modera Wealth Management LLC’s holdings in Cencora were worth $262,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the period. Householder Group Estate & Retirement Specialist LLC grew its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Kentucky Trust Co acquired a new position in Cencora in the 4th quarter valued at approximately $33,000. WASHINGTON TRUST Co lifted its position in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at $41,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 0.7 %

NYSE:COR opened at $251.40 on Thursday. The firm has a market cap of $48.75 billion, a price-to-earnings ratio of 35.76, a P/E/G ratio of 1.31 and a beta of 0.49. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company’s 50 day moving average is $243.25 and its 200-day moving average is $238.18.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is 31.29%.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at approximately $13,022,850. This represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,648 shares of company stock valued at $2,862,342. Company insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on COR shares. StockNews.com downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Tuesday. Mizuho started coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.